Pharsight

Lantheus Medcl patents expiration

1. Definity patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10022460 LANTHEUS MEDCL Lipid-encapsulated gas microsphere compositions and related methods
Dec, 2035

(11 years from now)

US11395856 LANTHEUS MEDCL Lipid-encapsulated gas microsphere compositions and related methods
Dec, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583207 LANTHEUS MEDCL Lipid-encapsulated gas microsphere compositions and related methods
Dec, 2035

(11 years from now)

US10583208 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(13 years from now)

US11529431 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(13 years from now)

US11857646 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(13 years from now)

US11266750 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(13 years from now)

US9789210 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(13 years from now)

US10588988 LANTHEUS MEDCL Methods and devices for preparation of ultrasound contrast agents
May, 2037

(13 years from now)

Drugs and Companies using PERFLUTREN ingredient

Market Authorisation Date: 31 July, 2001

Treatment: Method of using the drug substance/drug product for ultrasound imaging

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage

DEFINITY family patents

Family Patents